NCT06909565 - Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Biotech Hunter

Enrollment

6,000

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

December 31, 2029

Conditions

Percutaneous Coronary InterventionPeripheral Endovascular Intervention

Interventions

DRUG

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter

DRUG

Normal Saline (Placebo)

Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter

Trial Locations (5)

RECRUITING

Duke Cardiology, Morrisville

RECRUITING

PharmaTex Research, Amarillo

RECRUITING

Pacific Oaks Medical Group, Beverly Hills

RECRUITING

Radin Cardiovascular Medical Group, Inc, Newport Beach

RECRUITING

Advanced Heart Care LLC, Bridgewater